VANI
Vivani Medical, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$1.49
+7.19%Jul 15, 2026, 23:02 UTC
Vivani Medical announced it is preparing to begin human testing of its semaglutide implant in August.
Source:Jul 11, 2026, 17:15 UTC
Novo Nordisk signed an agreement with Vivani Medical to evaluate Vivani's experimental NPM-139 implant for continuous semaglutide delivery.
Source:Jul 7, 2026, 11:35 UTC
Vivani Medical signed an agreement with Novo Nordisk to enable Novo Nordisk to evaluate NPM-139, a semaglutide drug implant for chronic weight management.
Source:Jul 7, 2026, 00:00 UTC
Vivani Medical, Inc. signed an agreement for its subsidiary Cortigent to merge into ClearOne, Inc., with Cortigent becoming a wholly owned subsidiary of ClearOne.
Jun 30, 2026, 00:00 UTC
Vivani Medical, Inc. elected Gregg Williams, Daniel Bradbury, Aaron Mendelsohn, Adam Mendelsohn, and August Moretti as directors on June 24, 2026.